## Stephen Y Lai

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1581798/publications.pdf Version: 2024-02-01



**Stedhen ΥΙλι** 

#	Article	IF	CITATIONS
1	Evaluation of deep learning-based multiparametric MRI oropharyngeal primary tumor auto-segmentation and investigation of input channel effects: Results from a prospective imaging registry. Clinical and Translational Radiation Oncology, 2022, 32, 6-14.	0.9	28
2	Risk factors associated with patientâ€reported fatigue among longâ€ŧerm oropharyngeal carcinoma survivors. Head and Neck, 2022, 44, 952-963.	0.9	2
3	Outcomes after definitive surgery for mandibular osteoradionecrosis. Head and Neck, 2022, 44, 1313-1323.	0.9	3
4	Genetic susceptibility to patient-reported xerostomia among long-term oropharyngeal cancer survivors. Scientific Reports, 2022, 12, 6662.	1.6	2
5	Unilateral Radiotherapy for Tonsillar Cancer: Treatment Outcomes in the Era of Human Papilloma Virus (HPV), Positron-emission Tomography (PET) and Intensity-modulated Radiation Therapy (IMRT). International Journal of Radiation Oncology Biology Physics, 2022, , .	0.4	6
6	Three-Dimensional Evaluation of Isodose Radiation Volumes in Cases of Severe Mandibular Osteoradionecrosis for the Prediction of Recurrence after Segmental Resection. Journal of Personalized Medicine, 2022, 12, 834.	1.1	0
7	Hypomagnesemia and incidence of osteoradionecrosis in patients with head and neck cancers. Head and Neck, 2021, 43, 613-621.	0.9	2
8	Ultraâ€small superparamagnetic iron oxide (USPIO) magnetic resonance imaging in benign mixed tumor of the parotid gland. Clinical Case Reports (discontinued), 2021, 9, 123-127.	0.2	3
9	Self-Reported Trismus: prevalence, severity and impact on quality of life in oropharyngeal cancer survivorship: a cross-sectional survey report from a comprehensive cancer center. Supportive Care in Cancer, 2021, 29, 1825-1835.	1.0	17
10	Development of a rational strategy for integration of lactate dehydrogenase A suppression into therapeutic algorithms for head and neck cancer. British Journal of Cancer, 2021, 124, 1670-1679.	2.9	7
11	The impact of induction and/or concurrent chemoradiotherapy on acute and late patientâ€reported symptoms in oropharyngeal cancer: Application of a mixedâ€model analysis of a prospective observational cohort registry. Cancer, 2021, 127, 2453-2464.	2.0	7
12	Comparison of selective excitation and multi-echo chemical shift encoding for imaging of hyperpolarized [1-13C]pyruvate. Journal of Magnetic Resonance, 2021, 325, 106927.	1.2	4
13	Computed Tomography Radiomics Kinetics as Early Imaging Correlates of Osteoradionecrosis in Oropharyngeal Cancer Patients. Frontiers in Artificial Intelligence, 2021, 4, 618469.	2.0	8
14	Reply to N. Hirshoren et al and D. Chakrabarti et al. Journal of Clinical Oncology, 2021, 39, 1600-1601.	0.8	1
15	Risk and Clinical Risk Factors Associated With Late Lower Cranial Neuropathy in Long-term Oropharyngeal Squamous Cell Carcinoma Survivors. JAMA Otolaryngology - Head and Neck Surgery, 2021, 147, 469.	1.2	9
16	Novel Anaplastic Thyroid Cancer PDXs and Cell Lines: Expanding Preclinical Models of Genetic Diversity. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e4652-e4665.	1.8	8
17	Dysphagia profiles after primary transoral robotic surgery or radiation for oropharyngeal cancer: A registry analysis. Head and Neck, 2021, 43, 2883-2895.	0.9	6
18	A High-throughput Approach to Identify Effective Systemic Agents for the Treatment of Anaplastic Thyroid Carcinoma. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 2962-2978.	1.8	10

Stephen Y Lai

#	Article	IF	CITATIONS
19	Association of Risk Factors With Patient-Reported Voice and Speech Symptoms Among Long-term Survivors of Oropharyngeal Cancer. JAMA Otolaryngology - Head and Neck Surgery, 2021, 147, 615.	1.2	5
20	Manual Therapy for Fibrosis-Related Late Effect Dysphagia in head and neck cancer survivors: the pilot MANTLE trial. BMJ Open, 2021, 11, e047830.	0.8	6
21	Determinants of patientâ€reported xerostomia among longâ€term oropharyngeal cancer survivors. Cancer, 2021, 127, 4470-4480.	2.0	14
22	Advances in Imaging for HPV-Related Oropharyngeal Cancer: Applications to Radiation Oncology. Seminars in Radiation Oncology, 2021, 31, 371-388.	1.0	16
23	Normal Tissue Complication Probability (NTCP) Prediction Model for Osteoradionecrosis of the Mandible in Patients With Head and Neck Cancer After Radiation Therapy: Large-Scale Observational Cohort. International Journal of Radiation Oncology Biology Physics, 2021, 111, 549-558.	0.4	19
24	Delineating copy number and clonal substructure in human tumors from single-cell transcriptomes. Nature Biotechnology, 2021, 39, 599-608.	9.4	306
25	Intensity standardization methods in magnetic resonance imaging of head and neck cancer. Physics and Imaging in Radiation Oncology, 2021, 20, 88-93.	1.2	16
26	Outcomes of carotidâ€sparing IMRT for T1 glottic cancer: Comparison with conventional radiation. Laryngoscope, 2020, 130, 146-153.	1.1	25
27	Disruption of TP63-miR-27a* Feedback Loop by Mutant TP53 in Head and Neck Cancer. Journal of the National Cancer Institute, 2020, 112, 266-277.	3.0	5
28	Persistent and Chronic Postoperative Opioid Use in a Cohort of Patients with Oral Tongue Squamous Cell Carcinoma. Pain Medicine, 2020, 21, 1061-1067.	0.9	17
29	Evolving Evidence in Support of Sentinel Lymph Node Biopsy for Early-Stage Oral Cavity Cancer. Journal of Clinical Oncology, 2020, 38, 3983-3986.	0.8	15
30	Development and application of an elastic net logistic regression model to investigate the impact of cardiac substructure dose on radiation-induced pericardial effusion in patients with NSCLC. Acta Oncológica, 2020, 59, 1193-1200.	0.8	6
31	Cancer Surgery Scheduling During and After the COVID-19 First Wave. Annals of Surgery, 2020, 272, e106-e111.	2.1	26
32	Evaluation of Overall Survival in Patients With Anaplastic Thyroid Carcinoma, 2000-2019. JAMA Oncology, 2020, 6, 1397.	3.4	183
33	Quantitative Dynamic Contrast-Enhanced MRI Identifies Radiation-Induced Vascular Damage in Patients With Advanced Osteoradionecrosis: Results of a Prospective Study. International Journal of Radiation Oncology Biology Physics, 2020, 108, 1319-1328.	0.4	13
34	Metabolic, Radiation, and Medication Induced Sialadenitis. Current Otorhinolaryngology Reports, 2020, 8, 402-408.	0.2	0
35	Tobacco exposure as a major modifier of oncologic outcomes in human papillomavirus (HPV) associated oropharyngeal squamous cell carcinoma. BMC Cancer, 2020, 20, 912.	1.1	31
36	Head and neck cancer patient images for determining autoâ€segmentation accuracy in T2â€weighted magnetic resonance imaging through expert manual segmentations. Medical Physics, 2020, 47, 2317-2322.	1.6	29

Stephen Y Lai

#	Article	IF	CITATIONS
37	Dose–volume correlates of the prevalence of patient-reported trismus in long-term survivorship after oropharyngeal IMRT: A cross-sectional dosimetric analysis. Radiotherapy and Oncology, 2020, 149, 142-149.	0.3	11
38	Changing practice patterns in head and neck oncologic surgery in the early COVID â€19 era. Head and Neck, 2020, 42, 1179-1186.	0.9	34
39	Recommendations for head and neck surgical oncology practice in a setting of acute severe resource constraint during the COVID-19 pandemic: an international consensus. Lancet Oncology, The, 2020, 21, e350-e359.	5.1	96
40	Effect of Radiation on DCE-MRI Pharmacokinetic Parameters in a Rabbit Model of Compromised Maxillofacial Wound Healing: A Pilot Study. Journal of Oral and Maxillofacial Surgery, 2020, 78, 1034.e1-1034.e10.	0.5	3
41	Acquisition of Cisplatin Resistance Shifts Head and Neck Squamous Cell Carcinoma Metabolism toward Neutralization of Oxidative Stress. Cancers, 2020, 12, 1670.	1.7	33
42	Data from a terminated study on iron oxide nanoparticle magnetic resonance imaging for head and neck tumors. Scientific Data, 2020, 7, 63.	2.4	6
43	Automatic registration of 2D MR cine images for swallowing motion estimation. PLoS ONE, 2020, 15, e0228652.	1.1	4
44	Head and neck surgical oncology in the time of a pandemic: Subsiteâ€specific triage guidelines during the <scp>COVID</scp> â€19 pandemic. Head and Neck, 2020, 42, 1194-1201.	0.9	38
45	Neurologic sequelae following radiation with and without chemotherapy for oropharyngeal cancer: Patient reported outcomes study. Head and Neck, 2020, 42, 2137-2144.	0.9	3
46	Endocrine surgery in the Coronavirus disease 2019 pandemic: Surgical Triage Guidelines. Head and Neck, 2020, 42, 1325-1328.	0.9	29
47	Chronic radiation-associated dysphagia in oropharyngeal cancer survivors: Towards age-adjusted dose constraints for deglutitive muscles. Clinical and Translational Radiation Oncology, 2019, 18, 16-22.	0.9	24
48	Complete Surgical Resection Following Neoadjuvant Dabrafenib Plus Trametinib in <i>BRAF<sup>V600E</sup></i> -Mutated Anaplastic Thyroid Carcinoma. Thyroid, 2019, 29, 1036-1043.	2.4	156
49	Prospective quantitative quality assurance and deformation estimation of MRI-CT image registration in simulation of head and neck radiotherapy patients. Clinical and Translational Radiation Oncology, 2019, 18, 120-127.	0.9	24
50	Contemporary Approach to Locally Advanced Oral Cavity Squamous Cell Carcinoma. Current Oncology Reports, 2019, 21, 99.	1.8	18
51	Swallowingâ€related outcomes associated with late lower cranial neuropathy in longâ€ŧerm oropharyngeal cancer survivors: crossâ€sectional survey analysis. Head and Neck, 2019, 41, 3880-3894.	0.9	14
52	Dysphagia After Primary Transoral Robotic Surgery With Neck Dissection vs Nonsurgical Therapy in Patients With Low- to Intermediate-Risk Oropharyngeal Cancer. JAMA Otolaryngology - Head and Neck Surgery, 2019, 145, 1053.	1.2	51
53	Risk of second primary malignancies in head and neck cancer patients treated with definitive radiotherapy. Npj Precision Oncology, 2019, 3, 22.	2.3	31
54	ASCO Neck Dissection Guidelines Response Letter. Journal of Oncology Practice, 2019, 15, 560-561.	2.5	1

#	Article	IF	CITATIONS
55	Incidental detection of oropharyngeal cancer with fluciclovine PET. Head and Neck, 2019, 41, E141-E145.	0.9	3
56	Surgical consensus guidelines on sentinel node biopsy (SNB) in patients with oral cancer. Head and Neck, 2019, 41, 2655-2664.	0.9	77
57	Comprehensive Genetic Characterization of Human Thyroid Cancer Cell Lines: A Validated Panel for Preclinical Studies. Clinical Cancer Research, 2019, 25, 3141-3151.	3.2	115
58	Usefulness of surveillance imaging in patients with head and neck cancer who are treated with definitive radiotherapy. Cancer, 2019, 125, 1823-1829.	2.0	28
59	Development and Characterization of a Rabbit Model of Compromised Maxillofacial Wound Healing. Tissue Engineering - Part C: Methods, 2019, 25, 160-167.	1.1	8
60	Sebaceous carcinoma: evidence-based clinical practice guidelines. Lancet Oncology, The, 2019, 20, e699-e714.	5.1	116
61	Imaging-Genomic Study of Head and Neck Squamous Cell Carcinoma: Associations Between Radiomic Phenotypes and Genomic Mechanisms via Integration of The Cancer Genome Atlas and The Cancer Imaging Archive. JCO Clinical Cancer Informatics, 2019, 3, 1-9.	1.0	43
62	A prospective longitudinal assessment of MRI signal intensity kinetics of non-target muscles in patients with advanced stage oropharyngeal cancer in relationship to radiotherapy dose and post-treatment radiation-associated dysphagia: Preliminary findings from a randomized trial. Radiotherapy and Oncology 2019, 130, 46-55	0.3	14
63	Singleâ€item discrimination of qualityâ€ofâ€ife–altering dysphagia among 714 longâ€term oropharyngeal cancer survivors: Comparison of patientâ€reported outcome measures of swallowing. Cancer, 2019, 125, 1654-1664.	2.0	21
64	Role and Efficacy of Sentinel Lymph Node Biopsy in Oral Cavity Squamous Cell Carcinoma. Difficult Decisions in Surgery: an Evidence-based Approach, 2019, , 51-64.	0.0	0
65	Influence of parameter accuracy on pharmacokinetic analysis of hyperpolarized pyruvate. Magnetic Resonance in Medicine, 2018, 79, 3239-3248.	1.9	23
66	Three-dimensional imaging assessment of anatomic invasion and volumetric considerations for chemo/radiotherapy-based laryngeal preservation in T3 larynx cancer. Oral Oncology, 2018, 79, 1-8.	0.8	6
67	Cisplatin generates oxidative stress which is accompanied by rapid shifts in central carbon metabolism. Scientific Reports, 2018, 8, 4306.	1.6	77
68	Management of the lateral neck compartment in patients with sporadic medullary thyroid cancer. Head and Neck, 2018, 40, 79-85.	0.9	25
69	Grading Dysphagia as a Toxicity of Head and Neck Cancer: Differences in Severity Classification Based on MBS DIGEST and Clinical CTCAE Grades. Dysphagia, 2018, 33, 185-191.	1.0	23
70	Expiratory muscle strength training for radiationâ€associated aspiration after head and neck cancer: A case series. Laryngoscope, 2018, 128, 1044-1051.	1.1	50
71	Association of Lymph Node Density With Survival of Patients With Papillary Thyroid Cancer. JAMA Otolaryngology - Head and Neck Surgery, 2018, 144, 108.	1.2	49
72	Cough strength and expiratory force in aspirating and nonaspirating postradiation head and neck cancer survivors. Laryngoscope, 2018, 128, 1615-1621.	1.1	18

#	Article	IF	CITATIONS
73	Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. Nature Medicine, 2018, 24, 1649-1654.	15.2	592
74	Predicting treatment Response based on Dual assessment of magnetic resonance Imaging kinetics and Circulating Tumor cells in patients with Head and Neck cancer (PREDICT-HN): matching â€ĩliquid biopsy' and quantitative tumor modeling. BMC Cancer, 2018, 18, 903.	1,1	14
75	Symptom Burden Associated With Late Lower Cranial Neuropathy in Long-term Oropharyngeal Cancer Survivors. JAMA Otolaryngology - Head and Neck Surgery, 2018, 144, 1066.	1.2	23
76	Magnetic Resonance-based Response Assessment and Dose Adaptation in Human Papilloma Virus Positive Tumors of the Oropharynx treated with Radiotherapy (MR-ADAPTOR): An R-IDEAL stage 2a-2b/Bayesian phase II trial. Clinical and Translational Radiation Oncology, 2018, 13, 19-23.	0.9	41
77	Ageâ€adjusted comorbidity and survival in locally advanced laryngeal cancer. Head and Neck, 2018, 40, 2060-2069.	0.9	20
78	Prospective in silico study of the feasibility and dosimetric advantages of MRI-guided dose adaptation for human papillomavirus positive oropharyngeal cancer patients compared with standard IMRT. Clinical and Translational Radiation Oncology, 2018, 11, 11-18.	0.9	27
79	Radiotherapy dose–volume parameters predict videofluoroscopy-detected dysphagia per DIGEST after IMRT for oropharyngeal cancer: Results of a prospective registry. Radiotherapy and Oncology, 2018, 128, 442-451.	0.3	28
80	Effect of Tumor Size and Minimal Extrathyroidal Extension in Patients with Differentiated Thyroid Cancer. Thyroid, 2018, 28, 982-990.	2.4	62
81	Self-reported oral morbidities in long-term oropharyngeal cancer survivors: A cross-sectional survey of 906 survivors. Oral Oncology, 2018, 84, 88-94.	0.8	9
82	Incompletely treated malignancies of the major salivary gland: Toward evidenceâ€based care. Head and Neck, 2018, 40, 1630-1638.	0.9	8
83	Comparing Intensity-Modulated Proton Therapy With Intensity-Modulated Photon Therapy for Oropharyngeal Cancer: The Journey From Clinical Trial Concept to Activation. Seminars in Radiation Oncology, 2018, 28, 108-113.	1.0	26
84	A prospective in silico analysis of interdisciplinary and interobserver spatial variability in post-operative target delineation of high-risk oral cavity cancers: Does physician specialty matter?. Clinical and Translational Radiation Oncology, 2018, 12, 40-46.	0.9	16
85	Machine Learning Applications in Head and Neck Radiation Oncology: Lessons From Open-Source Radiomics Challenges. Frontiers in Oncology, 2018, 8, 294.	1.3	37
86	Xerostomia. , 2018, , 175-183.		0
87	Long-Term, Prospective Performance of the MDÂAnderson Dysphagia Inventory in "Low-Intermediate Risk―Oropharyngeal Carcinoma After Intensity Modulated Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2017, 97, 700-708.	0.4	46
88	Patterns of Treatment Failure in Anaplastic Thyroid Carcinoma. Thyroid, 2017, 27, 672-681.	2.4	111
89	Symptom burden and dysphagia associated with osteoradionecrosis in long-term oropharynx cancer survivors: A cohort analysis. Oral Oncology, 2017, 66, 75-80.	0.8	26
90	Facilitating anaplastic thyroid cancer specialized treatment: A model for improving access to multidisciplinary care for patients with anaplastic thyroid cancer. Head and Neck, 2017, 39, 1291-1295.	0.9	22

#	Article	IF	CITATIONS
91	Quantitative pretreatment CT volumetry: Association with oncologic outcomes in patients with T4a squamous carcinoma of the larynx. Head and Neck, 2017, 39, 1609-1620.	0.9	18
92	Delayed lower cranial neuropathy after oropharyngeal intensityâ€modulated radiotherapy: A cohort analysis and literature review. Head and Neck, 2017, 39, 1516-1523.	0.9	32
93	Intensity-modulated proton therapy and osteoradionecrosis in oropharyngeal cancer. Radiotherapy and Oncology, 2017, 123, 401-405.	0.3	73
94	Predicting two-year longitudinal MD Anderson Dysphagia Inventory outcomes after intensity modulated radiotherapy for locoregionally advanced oropharyngeal carcinoma. Laryngoscope, 2017, 127, 842-848.	1.1	37
95	Radiation therapy dose is associated with improved survival for unresected anaplastic thyroid carcinoma: Outcomes from the National Cancer Data Base. Cancer, 2017, 123, 1653-1661.	2.0	55
96	Dose-volume correlates of mandibular osteoradionecrosis in Oropharynx cancer patients receiving intensity-modulated radiotherapy: Results from a case-matched comparison. Radiotherapy and Oncology, 2017, 124, 232-239.	0.3	69
97	Patterns-of-failure guided biological target volume definition for head and neck cancer patients: FDG-PET and dosimetric analysis of dose escalation candidate subregions. Radiotherapy and Oncology, 2017, 124, 248-255.	0.3	32
98	Cognitive function and patientâ€reported memory problems after radiotherapy for cancers at the skull base: A crossâ€sectional survivorship study using the Telephone Interview for Cognitive Status and the MD Anderson Symptom Inventoryâ€Head and Neck Module. Head and Neck, 2017, 39, 2048-2056.	0.9	5
99	Adjuvant External Beam Radiotherapy in Locally Advanced Differentiated Thyroid Cancer. JAMA Otolaryngology - Head and Neck Surgery, 2017, 143, 1244.	1.2	39
100	Real-Time Genomic Characterization Utilizing Circulating Cell-Free DNA in Patients with Anaplastic Thyroid Carcinoma. Thyroid, 2017, 27, 81-87.	2.4	69
101	Dynamic Imaging Grade of Swallowing Toxicity (DIGEST): Scale development and validation. Cancer, 2017, 123, 62-70.	2.0	149
102	Reduced feeding tube duration with intensityâ€nodulated radiation therapy for head and neck cancer: A Surveillance, Epidemiology, and End Resultsâ€Medicare Analysis. Cancer, 2017, 123, 283-293.	2.0	24
103	Feeding Tube Utilization in Patients with Salivary Cland Malignancies. Otolaryngology - Head and Neck Surgery, 2017, 156, 109-117.	1.1	1
104	Long-term patient reported outcomes following radiation therapy for oropharyngeal cancer: cross-sectional assessment of a prospective symptom survey in patients ≥65Åyears old. Radiation Oncology, 2017, 12, 150.	1.2	25
105	Patterns of locoregional failure following post-operative intensity-modulated radiotherapy to oral cavity cancer: quantitative spatial and dosimetric analysis using a deformable image registration workflow. Radiation Oncology, 2017, 12, 129.	1.2	8
106	Outcomes of oral cavity cancer patients treated with surgery followed by postoperative intensity modulated radiation therapy. Oral Oncology, 2017, 72, 90-97.	0.8	28
107	Metabolic interrogation as a tool to optimize chemotherapeutic regimens. Oncotarget, 2017, 8, 18154-18165.	0.8	8
108	Small-molecule inhibition of STAT3 in radioresistant head and neck squamous cell carcinoma. Oncotarget, 2016, 7, 26307-26330.	0.8	75

#	Article	IF	CITATIONS
109	Salvage total laryngectomy after externalâ€beam radiotherapy: A 20â€year experience. Head and Neck, 2016, 38, E1962-8.	0.9	50
110	Improving patient outcomes through multidisciplinary treatment planning conference. Head and Neck, 2016, 38, E1820-5.	0.9	25
111	Treatment and survival of patients with insular thyroid carcinoma: 508 cases from the National Cancer Data Base. Head and Neck, 2016, 38, 906-912.	0.9	14
112	Prognostic value of pretherapy platelet elevation in oropharyngeal cancer patients treated with chemoradiation. International Journal of Cancer, 2016, 138, 1290-1297.	2.3	17
113	Magnetic Resonance Imaging of Glucose Uptake and Metabolism in Patients with Head and Neck Cancer. Scientific Reports, 2016, 6, 30618.	1.6	62
114	Osteoradionecrosis in patients with salivary gland malignancies. Oral Oncology, 2016, 57, 1-5.	0.8	9
115	Magnetic resonance imaging of swallowing-related structures in nasopharyngeal carcinoma patients receiving IMRT: Longitudinal dose–response characterization of quantitative signal kinetics. Radiotherapy and Oncology, 2016, 118, 315-322.	0.3	21
116	The role of elective nodal irradiation for esthesioneuroblastoma patients with clinically negative neck. Practical Radiation Oncology, 2016, 6, 241-247.	1.1	41
117	Beyond mean pharyngeal constrictor dose for beam path toxicity in non-target swallowing muscles: Dose–volume correlates of chronic radiation-associated dysphagia (RAD) after oropharyngeal intensity modulated radiotherapy. Radiotherapy and Oncology, 2016, 118, 304-314.	0.3	85
118	Longâ€ŧerm outcomes after multidisciplinary management of T3 laryngeal squamous cell carcinomas: Improved functional outcomes and survival with modern therapeutic approaches. Head and Neck, 2016, 38, 1739-1751.	0.9	33
119	A novel perfused Bloch–McConnell simulator for analyzing the accuracy of dynamic hyperpolarized MRS. Medical Physics, 2016, 43, 854-864.	1.6	8
120	Development and Feasibility of a Specialty-Specific National Surgical Quality Improvement Program (NSQIP). JAMA Otolaryngology - Head and Neck Surgery, 2016, 142, 321.	1.2	41
121	Allele-Specific Reprogramming of Cancer Metabolism by the Long Non-coding RNA CCAT2. Molecular Cell, 2016, 61, 520-534.	4.5	142
122	Consensus on the Existence of Functional Erythropoietin Receptors on Cancer Cells. JAMA Oncology, 2016, 2, 134.	3.4	15
123	Intravoxel incoherent motion imaging kinetics during chemoradiotherapy for human papillomavirus-associated squamous cell carcinoma of the oropharynx: preliminary results from a prospective pilot study. NMR in Biomedicine, 2015, 28, 1645-1654.	1.6	51
124	Sialendoscopy for Patients with Radioiodine-Induced Sialadenitis and Xerostomia. Thyroid, 2015, 25, 834-838.	2.4	53
125	Mitochondrial Metabolism as a Treatment Target in Anaplastic Thyroid Cancer. Seminars in Oncology, 2015, 42, 915-922.	0.8	33
126	Prospective observer and software-based assessment of magnetic resonance imaging quality in head and neck cancer: Should standard positioning and immobilization be required for radiation therapy applications?. Practical Radiation Oncology, 2015, 5, e299-e308.	1.1	31

#	Article	IF	CITATIONS
127	Lymphedema Outcomes in Patients with Head and Neck Cancer. Otolaryngology - Head and Neck Surgery, 2015, 152, 284-291.	1.1	91
128	Development and Characterization of Six New Human Papillary Thyroid Carcinoma Cell Lines. Journal of Clinical Endocrinology and Metabolism, 2015, 100, E243-E252.	1.8	27
129	[99mTc]Tilmanocept Accurately Detects Sentinel Lymph Nodes and Predicts Node Pathology Status in Patients with Oral Squamous Cell Carcinoma of the Head and Neck: Results of a Phase III Multi-institutional Trial. Annals of Surgical Oncology, 2015, 22, 3708-3715.	0.7	109
130	An audit and feedback system for effective quality improvement in head and neck surgery: Can we become better surgeons?. Cancer, 2015, 121, 1581-1587.	2.0	24
131	Single agent nanoparticle for radiotherapy and radio-photothermal therapy in anaplastic thyroid cancer. Biomaterials, 2015, 57, 41-49.	5.7	115
132	Acute Tumor Lactate Perturbations as a Biomarker of Genotoxic Stress: Development of a Biochemical Model. Molecular Cancer Therapeutics, 2015, 14, 2901-2908.	1.9	17
133	High-throughput hyperpolarized 13 C metabolic investigations using a multi-channel acquisition system. Journal of Magnetic Resonance, 2015, 260, 20-27.	1.2	11
134	Metabolic Imaging as a Biomarker of Early Radiation Response in Tumors. Clinical Cancer Research, 2015, 21, 4996-4998.	3.2	10
135	Association of TERT Promoter Mutation, But Not BRAF Mutation, With Increased Mortality in PTC. Journal of Clinical Endocrinology and Metabolism, 2015, 100, E1550-E1559.	1.8	58
136	Kinetic Modeling and Constrained Reconstruction of Hyperpolarized [1-13C]-Pyruvate Offers Improved Metabolic Imaging of Tumors. Cancer Research, 2015, 75, 4708-4717.	0.4	69
137	Thyroid Gland Malignancies. Hematology/Oncology Clinics of North America, 2015, 29, 1123-1143.	0.9	18
138	Feasibility of multianimal hyperpolarized <sup>13</sup> C MRS. Magnetic Resonance in Medicine, 2015, 73, 1726-1732.	1.9	5
139	Regulation of Receptor Tyrosine Kinases by miRNA: Overexpression of miRNA Using Lentiviral Inducible Expression Vectors. Methods in Molecular Biology, 2015, 1233, 135-147.	0.4	3
140	Evaluation of Hyperpolarized [1-13C]-Pyruvate by Magnetic Resonance to Detect Ionizing Radiation Effects in Real Time. PLoS ONE, 2014, 9, e87031.	1.1	36
141	Sorafenib in Metastatic Thyroid Cancer: A Systematic Review. Oncologist, 2014, 19, 251-258.	1.9	95
142	Radial spectroscopic MRI of hyperpolarized [1- <sup>13</sup> C] pyruvate at 7 tesla. Magnetic Resonance in Medicine, 2014, 72, 986-995.	1.9	28
143	Mutational Landscape of Aggressive Cutaneous Squamous Cell Carcinoma. Clinical Cancer Research, 2014, 20, 6582-6592.	3.2	493
144	Src inhibitors in suppression of papillary thyroid carcinoma growth. Head and Neck, 2014, 36, 375-384.	0.9	18

#	Article	IF	CITATIONS
145	In Reply. Oncologist, 2014, 19, e4-e4.	1.9	0
146	Detection of Thyroid Cancer Stem Cells in Papillary Thyroid Carcinoma. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 536-544.	1.8	45
147	Sentinel Lymph Node Biopsy for Oral Cancer: Supporting Evidence and Recent Novel Developments. Current Oncology Reports, 2014, 16, 385.	1.8	8
148	Correction: Tumor grafts derived from patients with head and neck squamous carcinoma authentically maintain the molecular and Histologic characteristics of human cancers. Journal of Translational Medicine, 2014, 12, 67.	1.8	0
149	Chemoradiotherapy for maxillary sinus adenoid cystic carcinoma using superselective intraâ€arterial infusion via a superficial temporal artery. Head and Neck, 2013, 35, E89-93.	0.9	11
150	Tumor grafts derived from patients with head and neck squamous carcinoma authentically maintain the molecular and histologic characteristics of human cancers. Journal of Translational Medicine, 2013, 11, 198.	1.8	61
151	Eat and Exercise During Radiotherapy or Chemoradiotherapy for Pharyngeal Cancers. JAMA Otolaryngology - Head and Neck Surgery, 2013, 139, 1127.	1.2	194
152	Phosphaturic mesenchymal tumor: a report of 6 patients treated at a single institution and comparison with reported series. Annals of Diagnostic Pathology, 2013, 17, 319-321.	0.6	23
153	Gastrostomy tube placement in patients with oropharyngeal carcinoma treated with radiotherapy or chemoradiotherapy: Factors affecting placement and dependence. Head and Neck, 2013, 35, 1634-1640.	0.9	91
154	A throughputâ€optimized array system for multipleâ€mouse MRI. NMR in Biomedicine, 2013, 26, 237-247.	1.6	4
155	Multidisciplinary Management of Lacrimal Sac/Nasolacrimal Duct Carcinomas. Ophthalmic Plastic and Reconstructive Surgery, 2013, 29, 454-457.	0.4	50
156	Gastrostomy tube placement in patients with hypopharyngeal cancer treated with radiotherapy or chemoradiotherapy: Factors affecting placement and dependence. Head and Neck, 2013, 35, 1641-1646.	0.9	69
157	Coordinated Targeting of the EGFR Signaling Axis by MicroRNA-27a*. Oncotarget, 2013, 4, 1388-1398.	0.8	44
158	A Review of Safety, Efficacy, and Utilization of Erythropoietin, Darbepoetin, and Peginesatide for Patients with Cancer or Chronic Kidney Disease: A Report from the Southern Network on Adverse Reactions (SONAR). Seminars in Thrombosis and Hemostasis, 2012, 38, 783-796.	1.5	32
159	Superimposed Infection in Mandibular Osteoradionecrosis. Journal of Computer Assisted Tomography, 2012, 36, 725-731.	0.5	20
160	Glycolytic Inhibition Alters Anaplastic Thyroid Carcinoma Tumor Metabolism and Improves Response to Conventional Chemotherapy and Radiation. Molecular Cancer Therapeutics, 2012, 11, 1373-1380.	1.9	57
161	STAT5A-Mediated SOCS2 Expression Regulates Jak2 and STAT3 Activity Following c-Src Inhibition in Head and Neck Squamous Carcinoma. Clinical Cancer Research, 2012, 18, 127-139.	3.2	54
162	Targeting STAT3 inhibits growth and enhances radiosensitivity in head and neck squamous cell carcinoma. Oral Oncology, 2012, 48, 1220-1226.	0.8	81

#	Article	IF	CITATIONS
163	Functional relevance of miRNA* sequences in human disease. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2012, 731, 14-19.	0.4	72
164	Fast, reproducible measurement of the vascular input function in mice using constrained reconstruction and cardiac sampling. NMR in Biomedicine, 2011, 24, 373-384.	1.6	10
165	Prognostic factors in patients with highâ€risk locally advanced salivary gland cancers treated with surgery and postoperative radiotherapy. Head and Neck, 2011, 33, 318-323.	0.9	39
166	HIF-1–Dependent Stromal Adaptation to Ischemia Mediates <i>In Vivo</i> Tumor Radiation Resistance. Molecular Cancer Research, 2011, 9, 259-270.	1.5	24
167	Targeted Therapy of VEGFR2 and EGFR Significantly Inhibits Growth of Anaplastic Thyroid Cancer in an Orthotopic Murine Model. Clinical Cancer Research, 2011, 17, 2281-2291.	3.2	68
168	MEK Inhibitor PD0325901 Significantly Reduces the Growth of Papillary Thyroid Carcinoma Cells <i>In vitro</i> and <i>In vivo</i> . Molecular Cancer Therapeutics, 2010, 9, 1968-1976.	1.9	70
169	Radiosensitization and Stromal Imaging Response Correlates for the HIF-1 Inhibitor PX-478 Given with or without Chemotherapy in Pancreatic Cancer. Molecular Cancer Therapeutics, 2010, 9, 2057-2067.	1.9	77
170	Association Between Pharmaceutical Support and Basic Science Research on Erythropoiesis-Stimulating Agents. Archives of Internal Medicine, 2010, 170, 1490-8.	4.3	20
171	Pathology Quiz Case 2. JAMA Otolaryngology, 2010, 136, 841.	1.5	1
172	Induction Docetaxel, Cisplatin, and Cetuximab Followed by Concurrent Radiotherapy, Cisplatin, and Cetuximab and Maintenance Cetuximab in Patients With Locally Advanced Head and Neck Cancer. Journal of Clinical Oncology, 2010, 28, 5294-5300.	0.8	132
173	Quality and Performance Indicators in an Academic Department of Head and Neck Surgery. JAMA Otolaryngology, 2010, 136, 1212.	1.5	70
174	Defining the role of the JAK-STAT pathway in head and neck and thoracic malignancies: Implications for future therapeutic approaches. Drug Resistance Updates, 2010, 13, 67-78.	6.5	150
175	Management of Thyroid Neoplasms. , 2010, , 1750-1772.		8
176	Reassessments of ESAs for cancer treatment in the US and Europe. Oncology, 2010, 24, 260-8.	0.4	11
177	Intratumoral Epidermal Growth Factor Receptor Antisense DNA Therapy in Head and Neck Cancer: First Human Application and Potential Antitumor Mechanisms. Journal of Clinical Oncology, 2009, 27, 1235-1242.	0.8	63
178	Management of squamous cell carcinoma of the base of tongue with chemoradiation and brachytherapy. Head and Neck, 2009, 31, 1431-1438.	0.9	22
179	Stereotactic Body Radiotherapy for Recurrent Squamous Cell Carcinoma of the Head and Neck: Results of a Phase I Dose-Escalation Trial. International Journal of Radiation Oncology Biology Physics, 2009, 75, 1493-1500.	0.4	165
180	Head and neck cancer. Cancer, 2008, 113, 1911-1932.	2.0	197

#	Article	IF	CITATIONS
181	Treatment and survival outcomes based on histologic grading in patients with head and neck mucoepidermoid carcinoma. Cancer, 2008, 113, 2082-2089.	2.0	128
182	Minimally invasive videoâ€assisted thyroidectomy: Expanded indications and oncologic completeness. Head and Neck, 2008, 30, 1403-1407.	0.9	44
183	Reconstruction of the Throughâ€andâ€Through Anterior Mandibulectomy Defect: Indications and Limitations of the Doubleâ€6kin Paddle Fibular Free Flap. Laryngoscope, 2008, 118, 1329-1334.	1.1	26
184	Activated Vav2 modulates cellular invasion through Rac1 and Cdc42 in oral squamous cell carcinoma. Oral Oncology, 2008, 44, 683-688.	0.8	21
185	Venous Thromboembolism and Mortality Associated With Recombinant Erythropoietin and Darbepoetin Administration for the Treatment of Cancer-Associated Anemia. JAMA - Journal of the American Medical Association, 2008, 299, 914.	3.8	657
186	Reconstruction of the marginal mandibulectomy defect: an update. American Journal of Otolaryngology - Head and Neck Medicine and Surgery, 2007, 28, 363-366.	0.6	11
187	Head and neck squamous cell carcinoma cell lines: Established models and rationale for selection. Head and Neck, 2007, 29, 163-188.	0.9	209
188	Deferring Planned Neck Dissection Following Chemoradiation for Stage IV Head and Neck Cancer: The Utility of PET T. Laryngoscope, 2007, 117, 2129-2134.	1.1	115
189	Reconstruction of the Lateral Mandibulectomy Defect: Management Based on Prognosis and Location and Volume of Soft Tissue Resection. Laryngoscope, 2006, 116, 2071-2080.	1.1	47
190	Understanding the Presence and Function of Erythropoietin Receptors on Cancer Cells. Journal of Clinical Oncology, 2006, 24, 4675-4676.	0.8	39
191	Erythropoietin-mediated activation of JAK-STAT signaling contributes to cellular invasion in head and neck squamous cell carcinoma. Oncogene, 2005, 24, 4442-4449.	2.6	157
192	High-risk non-melanoma skin cancer of the head and neck. Current Oncology Reports, 2005, 7, 154-158.	1.8	7
193	Erythropoietin Signaling Promotes Invasiveness of Human Head and Neck Squamous Cell Carcinoma. Neoplasia, 2005, 7, 537-543.	2.3	100
194	Radiology Quiz Case 2. JAMA Otolaryngology, 2004, 130, 1121.	1.5	0
195	Dysregulation of Hypoxia Inducible Factor-1?? in Head and Neck Squamous Cell Carcinoma Cell Lines Correlates With Invasive Potential. Laryngoscope, 2004, 114, 418-423.	1.1	25
196	Cutaneous malignancies of the head and neck. Operative Techniques in General Surgery, 2004, 6, 132-142.	0.0	1
197	Supracricoid partial laryngectomy with cricohyoidepiglottopexy. Operative Techniques in Otolaryngology - Head and Neck Surgery, 2003, 14, 34-39.	0.1	3
198	Tracheostomy: Demystifying an ancient technique. Operative Techniques in Otolaryngology - Head and Neck Surgery, 2003, 14, 51-54.	0.1	0

#	Article	IF	CITATIONS
199	Parotidectomy in the Treatment of Aggressive Cutaneous Malignancies. JAMA Otolaryngology, 2002, 128, 521.	1.5	45
200	Clinical Care Pathway for Head and Neck Cancer. JAMA Otolaryngology, 2002, 128, 258.	1.5	40
201	Identification of Upper Respiratory Bacterial Pathogens With the Electronic Nose. Laryngoscope, 2002, 112, 975-979.	1.1	72
202	Bilateral Squamous Cell Carcinoma of the External Auditory Canals. Laryngoscope, 2002, 112, 1003-1005.	1.1	17
203	Sphenoid Encephaloceles: Disease Management and Identification of Lesions Within the Lateral Recess of the Sphenoid Sinus. Laryngoscope, 2002, 112, 1800-1805.	1.1	113
204	Allergic rhinitis in children. Current Opinion in Otolaryngology and Head and Neck Surgery, 2001, 9, 359-364.	0.8	1
205	Genetic Evidence for an Additional Factor Required for Erythropoietin-Induced Signal Transduction. Blood, 1999, 94, 74-86.	0.6	25
206	Oligomerization and Scaffolding Functions of the Erythropoietin Receptor Cytoplasmic Tail. Journal of Biological Chemistry, 1999, 274, 5415-5421.	1.6	26
207	Heteromerization of the γc Chain with the Interleukin-9 Receptor α Subunit Leads to STAT Activation and Prevention of Apoptosis. Journal of Biological Chemistry, 1998, 273, 9255-9260.	1.6	82
208	Redundant and Selective Roles for Erythropoietin Receptor Tyrosines in Erythropoiesis In Vivo. Blood, 1998, 91, 870-878.	0.6	32
209	Redundant and Selective Roles for Erythropoietin Receptor Tyrosines in Erythropoiesis In Vivo. Blood, 1998, 91, 870-878.	0.6	1
210	Distinct Tyrosine Residues within the Interleukin-2 Receptor Î <sup>2</sup> Chain Drive Signal Transduction Specificity, Redundancy, and Diversity. Journal of Biological Chemistry, 1996, 271, 21381-21390.	1.6	69
211	Identification of a Variable Region within the Cytoplasmic Tail of the IL-2 Receptor Î <sup>2</sup> Chain That Is Required for Growth Signal Transduction. Journal of Biological Chemistry, 1995, 270, 22176-22181.	1.6	20
212	Growth Signal Transduction by the Human Interleukin-2 Receptor Requires Cytoplasmic Tyrosines of the β Chain and Non-tyrosine Residues of the γc Chain. Journal of Biological Chemistry, 1995, 270, 21729-21737.	1.6	65
213	Association of hearing loss and tinnitus symptoms with <scp>healthâ€related</scp> quality of life among <scp>longâ€term</scp> oropharyngeal cancer survivors. Cancer Medicine, 0, , .	1.3	3